调强放疗治疗淋巴结寡复发。
Intensity-modulated Radiation Therapy for Lymph Node Oligo-recurrence.
机构信息
Department of Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Japan
Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
出版信息
In Vivo. 2020 Sep-Oct;34(5):2587-2593. doi: 10.21873/invivo.12076.
BACKGROUND/AIM: This study aimed to evaluate the effect of intensity-modulated radiation therapy (IMRT) on the clinical outcomes of patients with lymph node (LN) oligo-recurrence and a controlled primary tumor.
PATIENTS AND METHODS
We retrospectively reviewed the medical records of 21 patients diagnosed with LN oligo-recurrence who received IMRT with curative intent. Patients with tumor of various primary sites and histopathological types were included in this study.
RESULTS
The 3-year overall survival (OS) and in-field progression-free survival (PFS) rates were 75% and 52%, respectively. Statistical analysis showed that lower dose to the gross tumor volume (GTV) and larger GTV were significantly associated with poorer OS; adenocarcinoma and lower dose to GTV were significantly associated with poorer in-field PFS. No patients experienced severe adverse events.
CONCLUSION
IMRT may provide a safe and effective treatment for patients with LN oligo-recurrence. Tumor dose-escalation sparing normal tissue using IMRT technology may improve the OS and in-field PFS.
背景/目的：本研究旨在评估调强放疗（IMRT）对淋巴结（LN）寡复发和控制原发肿瘤的患者临床结局的影响。
患者和方法
我们回顾性分析了 21 例接受根治性 IMRT 治疗的 LN 寡复发患者的病历。本研究纳入了来自不同原发部位和组织病理学类型的肿瘤患者。
结果
3 年总生存率（OS）和靶区内无进展生存率（PFS）分别为 75%和 52%。统计学分析显示，GTV 接受的较低剂量和较大 GTV 与较差的 OS 显著相关；腺癌和 GTV 接受的较低剂量与靶区内 PFS 较差显著相关。无患者发生严重不良事件。
结论
IMRT 可能为 LN 寡复发患者提供一种安全有效的治疗方法。使用 IMRT 技术对肿瘤进行剂量递增以保护正常组织可能会提高 OS 和靶区内 PFS。
Zotero 插件